Dechra Pharmaceuticals PLC Annual Report & Accounts for period ended 30 June 2013
the Business through Investment in our Pipeline
Find out more >
on our Veterinary Pharmaceuticals Product Strategy
Sustainable Growth and Value
Watch the video >
Our European Pharmaceuticals Segment continues to show progress and achieved sales of £168.7 million, an increase of 66.3%.
The sale of the Services business is a significant step forward in achieving our clearly defined strategic objective.
Our divestment of the Services Segment (announced on 10 July 2013) was a logical strategic step following the successful acquisition of Eurovet